Barclays’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $18.9M | Sell |
20,500
-21,600
| -51% | -$21.9M | ﹤0.01% | 1129 |
|
|
2025
Q4 | $45.2M | Sell |
42,100
-65,100
| -61% | -$62.2M | 0.01% | 827 |
|
|
2025
Q3 | $81.8M | Sell |
107,200
-17,100
| -14% | -$12.7M | 0.02% | 575 |
|
|
2025
Q2 | $96.9M | Buy |
124,300
+38,300
| +45% | +$29.8M | 0.02% | 477 |
|
|
2025
Q1 | $71M | Buy |
86,000
+46,700
| +119% | +$38.9M | 0.02% | 536 |
|
|
2024
Q4 | $30.3M | Sell |
39,300
-19,000
| -33% | -$15.7M | 0.01% | 884 |
|
|
2024
Q3 | $51.7M | Sell |
58,300
-53,000
| -48% | -$47.6M | 0.01% | 656 |
|
|
2024
Q2 | $101M | Buy |
111,300
+107,500
| +2,829% | +$86M | 0.03% | 389 |
|
|
2024
Q1 | $2.96M | Sell |
3,800
-39,600
| -91% | -$28.2M | ﹤0.01% | 2245 |
|
|
2023
Q4 | $25.3M | Buy |
+43,400
| New | +$25.3M | 0.01% | 959 |
|
|
2023
Q2 | – | Sell |
-51,800
| Closed | -$17.8M | – | 4836 |
|
|
2023
Q1 | $17.8M | Sell |
51,800
-86,600
| -63% | -$29.2M | 0.01% | 888 |
|
|
2022
Q4 | $50.6M | Buy |
+138,400
| New | +$49.1M | 0.02% | 481 |
|
|
2022
Q1 | – | Sell |
-10,000
| Closed | -$2.76M | – | 5327 |
|
|
2021
Q4 | $2.76M | Buy |
+10,000
| New | +$2.54M | ﹤0.01% | 2159 |
|
|
2021
Q3 | – | Sell |
-2,600
| Closed | -$597K | – | 4895 |
|
|
2021
Q2 | $597K | Hold |
2,600
| – | – | ﹤0.01% | 2969 |
|
|
2021
Q1 | $486K | Sell |
2,600
-28,500
| -92% | -$5.57M | ﹤0.01% | 3196 |
|
|
2020
Q4 | $5.25M | Buy |
31,100
+27,200
| +697% | +$4.06M | ﹤0.01% | 1495 |
|
|
2020
Q3 | $577K | Sell |
3,900
-31,500
| -89% | -$4.88M | ﹤0.01% | 3130 |
|
|
2020
Q2 | $5.81M | Sell |
35,400
-192,200
| -84% | -$29.5M | ﹤0.01% | 1267 |
|
|
2020
Q1 | $31.6M | Buy |
227,600
+134,000
| +143% | +$18.4M | 0.03% | 461 |
|
|
2019
Q4 | $12.3M | Sell |
93,600
-41,200
| -31% | -$4.78M | 0.01% | 1248 |
|
|
2019
Q3 | $15.1M | Buy |
134,800
+55,900
| +71% | +$6.22M | 0.01% | 1045 |
|
|
2019
Q2 | $8.74M | Sell |
78,900
-694,200
| -90% | -$81.7M | 0.01% | 1442 |
|
|
2019
Q1 | $100M | Buy |
773,100
+734,200
| +1,887% | +$89.3M | 0.07% | 232 |
|
|
2018
Q4 | $4.5M | Sell |
38,900
-127,000
| -77% | -$14.2M | ﹤0.01% | 1670 |
|
|
2018
Q3 | $17.8M | Sell |
165,900
-71,100
| -30% | -$7.11M | 0.01% | 920 |
|
|
2018
Q2 | $20.2M | Sell |
237,000
-5,400
| -2% | -$444K | 0.02% | 778 |
|
|
2018
Q1 | $18.8M | Buy |
242,400
+131,700
| +119% | +$10.6M | 0.01% | 876 |
|
|
2017
Q4 | $9.35M | Sell |
110,700
-47,200
| -30% | -$4.02M | 0.01% | 1222 |
|
|
2017
Q3 | $13.5M | Sell |
157,900
-52,400
| -25% | -$4.3M | 0.01% | 870 |
|
|
2017
Q2 | $17.3M | Buy |
210,300
+101,400
| +93% | +$8.27M | 0.02% | 676 |
|
|
2017
Q1 | $9.16M | Sell |
108,900
-1,826,100
| -94% | -$146M | 0.01% | 927 |
|
|
2016
Q4 | $142M | Buy |
1,935,000
+1,278,000
| +195% | +$95.2M | 0.15% | 102 |
|
|
2016
Q3 | $52.7M | Buy |
657,000
+472,400
| +256% | +$37.8M | 0.06% | 244 |
|
|
2016
Q2 | $14.5M | Buy |
184,600
+100,900
| +121% | +$7.6M | 0.02% | 654 |
|
|
2016
Q1 | $6.03M | Sell |
83,700
-25,100
| -23% | -$1.9M | 0.01% | 1047 |
|
|
2015
Q4 | $9.14M | Sell |
108,800
-74,200
| -41% | -$6.16M | 0.01% | 945 |
|
|
2015
Q3 | $15.2M | Sell |
183,000
-17,200
| -9% | -$1.45M | 0.02% | 717 |
|
|
2015
Q2 | $16.6M | Buy |
200,200
+122,500
| +158% | +$9.33M | 0.02% | 751 |
|
|
2015
Q1 | $5.59M | Sell |
77,700
-37,200
| -32% | -$2.65M | 0.01% | 1475 |
|
|
2014
Q4 | $7.81M | Sell |
114,900
-316,800
| -73% | -$21.4M | 0.01% | 1359 |
|
|
2014
Q3 | $27.6M | Buy |
431,700
+69,100
| +19% | +$4.37M | 0.03% | 560 |
|
|
2014
Q2 | $22.5M | Sell |
362,600
-193,200
| -35% | -$11.5M | 0.02% | 640 |
|
|
2014
Q1 | $32.2M | Sell |
555,800
-33,300
| -6% | -$1.86M | 0.04% | 454 |
|
|
2013
Q4 | $30M | Buy |
589,100
+171,700
| +41% | +$8.6M | 0.03% | 545 |
|
|
2013
Q3 | $20.9M | Sell |
417,400
-201,100
| -33% | -$10.5M | 0.02% | 647 |
|
|
2013
Q2 | $30.4M | Buy |
+618,500
| New | +$33.7M | 0.04% | 434 |
|
Other funds holding LLY
VCM
VPM
Barclays's LLY Position: Q1 2026 in Review
Barclays increased its Eli Lilly (LLY) stake by 11% in Q1 2026, buying an estimated $162M and bringing the position to 1,563,625 shares worth $1.44B. The position accounts for 0.35% of the portfolio, ranked #33.
Barclays first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.87B in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Barclays held 1,563,625 shares of Eli Lilly worth $1.44B as of Q1 2026.
- Barclays bought 159,958 Eli Lilly shares in Q1 2026, an estimated $162M.
- Eli Lilly made up 0.35% of Barclays's portfolio in Q1 2026, its #33 holding.
- Barclays first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
- Barclays's Eli Lilly position peaked at $1.87B in Q2 2024.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.